ArticleFrontiers in psychiatry2026
The independent predictive effect of insomnia symptoms before high-altitude exposure on acute mountain sickness: an observational study of healthy volunteers at 2726 m.
Article in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To examine the independent predictive role of symptoms of insomnia on the risk of acute mountain sickness (AMS) in healthy volunteers during a short-term extreme-altitude mountaineering activity. Methods: Fifteen healthy volunteers were recruited for a 3-day mountaineering expedition with a target altitude of 5,396 meters. Baseline symptoms of insomnia were assessed one week before departure at low altitude (Wuhan, 23 m) using the Athens Insomnia Scale (AIS). During the 3-day ascent, high-altitude insomnia symptoms and AMS symptoms were evaluated daily using the AIS and the 2018 Lake Louise Score (LLS), respectively. The primary analysis for AMS, based on LLS assessment (Day 2 post-arrival), was conducted at an altitude of 2726 m. Univariate and multivariate logistic regression analyses were conducted to examine the association between AIS scores and AMS. Results: The mean baseline AIS score of participants was 6.9, and the mean high-altitude AIS score was 10.7. During the expedition, AMS (defined as LLS≥3) occurred in 10 participants, with a mean LLS score of 4.3 among AMS cases. Univariate analysis showed that both baseline AIS score (OR = 2.994,95%CI:1.059-8.459, p<0.05) and high-altitude AIS score (OR = 3.901,95% CI: 1.124-13.544, p<0.05) were significantly positively associated with AMS risk. In multivariate analysis, after adjusting for age and gender, baseline AIS score remained an independent predictor of AMS (OR = 3.074, 95% CI:1.023-8.638, p<0.05), whereas the high-altitude AIS score did not yield a stable estimate due to complete separation in the model. Univariate analysis indicated that ΔAIS (change in AIS score) did not show a significant effect on AMS (p>0.05). Conclusion: Baseline AIS scores serve as an independent predictor of AMS, supporting the incorporation of sleep assessment into pre-ascent. health screening for high-altitude mountaineering. However, this finding is derived from a small sample within a specific cohort; its predictive utility and generalizability must be independently validated in future studies with larger and more diverse populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.